SCHEMBL4635361

SCHEMBL4635361

COC(=O)C(O)c1c(C)c(C(=O)c2ccccc2)c2ccccn12

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 7/20 0.46
KMT2A Q03164 4/20 0.46
MAPT P10636 4/20 0.46
KDM4E B2RXH2 4/20 0.46
MEN1 O00255 3/20 0.46
L3MBTL1 Q9Y468 2/20 0.46
HPGD P15428 2/20 0.45
NPSR1 Q6W5P4 2/20 0.45
HTT P42858 2/20 0.44
RXFP1 Q9HBX9 2/20 0.42
NPC1 O15118 2/20 0.42
GAA P10253 1/20 0.42
ATM Q13315 1/20 0.42
MAPK1 P28482 3/20 0.40
IDO1 P14902 2/20 0.40
CYP1A2 P05177 1/20 0.40
CYP3A4 P08684 1/20 0.40
HBB P68871 1/20 0.40
HIF1A Q16665 1/20 0.40
POLB P06746 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4635762 0.74 ALDH1A1 (0.55) ALDH1A1KMT2AMAPTKDM4EMEN1
SCHEMBL4635646 0.73 ALDH1A1 (0.61) ALDH1A1KMT2AMAPTKDM4EMEN1
SCHEMBL4635350 0.72 HTR6 (0.41) ALDH1A1KMT2AMAPTKDM4EMEN1
SCHEMBL4635948 0.69 ALDH1A1 (0.66) ALDH1A1KMT2AMAPTKDM4EMEN1
SCHEMBL3596956 0.68 MAPT (0.52) ALDH1A1KMT2AMAPTKDM4EMEN1
SCHEMBL6218548 0.68 MEN1 (0.56) ALDH1A1KMT2AMAPTKDM4EMEN1
SCHEMBL29059749 0.66 ALDH1A1 (0.49) ALDH1A1KMT2AMAPTKDM4EMEN1
SCHEMBL142911 0.64 HTT (0.59) ALDH1A1KMT2AMAPTKDM4EMEN1
Mandelic Acid, Methyl Ester SCHEMBL186900 0.63 KMT2A (0.67) ALDH1A1KMT2AMEN1HPGDMAPK1
Mandelic Acid, Methyl Ester SCHEMBL28228867 0.63 KMT2A (0.67) ALDH1A1KMT2AMEN1HPGDMAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080306109-A1 Indolizine Derivatives as Ligands of the Crth2 Receptor ARGENTA DISCOVERY LIMITED (GB) 2008-12-11 US disclosed
CN-101305001-A Indolizine derivatives as ligands of the CRTH2 receptor ARGENTA DISCOVERY LTD (GB) 2008-11-12 CN disclosed
EP-1931663-A1 IMDOLIZINE DERIVATIVES AS LIGANDS OF THE CRTH2 RECEPTOR Argenta Discovery Limited (GB) 2008-06-18 EP disclosed
WO-2007031747-A1 IMDOLIZINE DERIVATIVES AS LIGANDS OF THE CRTH2 RECEPTOR ARGENTA DISCOVERY LIMITED (GB) 2007-03-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080306109-A1 Indolizine Derivatives as Ligands of the Crth2 Receptor HRH4, HRH2, HRH3 ALDH1A1 3463/4885KMT2A 3092/4885MAPT 4777/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.